|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
1R41CA203456-01A1
|
$313,705
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Discovery of therapeutic antibodies targeting breast cancer metastasis using Enabled G-Protein-Coupled Receptors
|
1R43CA213832-01
|
$300,000
|
|
MILENI, MAURO
|
ABILITA BIO, INC.
|
|
The Madrina Network Web Portal
|
4R44CA177037-02
|
$587,225
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Novel Ras inhibitor prodrug for colorectal cancer
|
1R43CA206807-01
|
$300,000
|
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, INC.
|
|
Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes.
|
5R44CA180296-03
|
$877,393
|
|
STRAIGHT, BRIAN
|
AKROTOME IMAGING, INC.
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
2R01CA129637-06A1
|
$375,250
|
|
DIPERSIO, C. MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Signal transduction regulating tumor cell dissemination
|
2R01CA150344-28
|
$396,625
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Roles of formins in breast cancer invasion
|
1R21CA205262-01
|
$181,613
|
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
3U10CA014958-38S1
|
$144,167
|
$1,442
|
Sparano, Joseph
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-19
|
$581,591
|
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of macroH2A variants in cancer and senescence
|
5R01CA155232-06
|
$346,525
|
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-19
|
$484,821
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of tunneling nanotubes as a novel mode of tumor cell-macrophage communication
|
1F99CA212451-01
|
$45,076
|
|
HANNA, SAMER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
5R01CA170911-06
|
$346,525
|
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Training of Surgeons for Studies of the Tumor Microenvironment
|
5T32CA200561-02
|
$277,140
|
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
5R01CA160790-06
|
$522,889
|
|
MUESCH, ANNE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
5R01CA154755-07
|
$442,325
|
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
1R01CA201458-01A1
|
$382,013
|
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nemours Community Clinical Oncology Program
|
1U10CA176879-01
|
$558,366
|
$33,502
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Nemours NCI Community Oncology Research Program (NCORP)
|
5UG1CA189958-03
|
$992,500
|
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Advancing Dissemination and Implementation Research on Walking and Walkability: Developing Research Priorities
|
1R13CA203386-01
|
$10,000
|
|
KRAFT, KATHERINE
|
AMERICA WALKS, INC.
|
|
Integrative Molecular Epidemiology Workshop
|
4R25CA174664-04
|
$207,685
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-37
|
$14,566,378
|
$145,664
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American College of Radiology Imaging Network
|
3U10CA080098-14S2
|
$5,146,722
|
$51,467
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Integration of Palliative Care Training into Oncology
|
7R25CA163198-05
|
$169,710
|
|
VON ROENN, JAMIE
|
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
|
|
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
|
5R42CA183708-05
|
$133,116
|
|
PARSONS, CHRISTOPHER
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
Development of Transporter Targeted Platinum Drugs for Glioblastoma
|
1R43CA177013-01A1
|
$216,990
|
|
CHIEN, HUAN-CHIEH
|
APRICITY THERAPEUTICS, INC.
|
|
Combinatorial Inactivation of ERBB Receptors in Breast Cancer using Therapeutic Stapled Peptides
|
1R41CA203353-01
|
$300,000
|
|
CAMENISCH, TODD
|
ARIZONA CANCER THERAPEUTICS, LLC
|
|
Stand and Move at Work: A Group-Randomized Trial
|
5R01CA198971-02
|
$617,374
|
|
BUMAN, MATTHEW
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
5R01CA199948-02
|
$496,815
|
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Charge sensitive optical detection for high-throughput study of small molecules
|
1R33CA202834-01A1
|
$381,382
|
|
TAO, NONGJIAN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
1R44CA203199-01
|
$648,400
|
|
WINKLER, JAMES
|
ARVINAS, INC.
|
|
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers
|
1R41CA203436-01A1
|
$299,998
|
|
BROWN, ERIC
|
ATRIN PHARMACEUTICALS
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
1R01CA202769-01
|
$432,900
|
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
PNNL Proteome Characterization Center
|
1U24CA210955-01
|
$1,123,778
|
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
Bay Area Tumor Institute NCORP
|
5UG1CA189817-03
|
$730,000
|
|
BAILEY, LISA
|
BAY AREA TUMOR INSTITUTE
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-24
|
$486,165
|
$14,585
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-03
|
$587,321
|
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Investigating the mechanisms of CD44s splice isoform in breast cancer metastasis
|
7R01CA182467-04
|
$301,150
|
|
CHENG, CHONGHUI
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
1R01CA206476-01
|
$772,521
|
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
5R01CA190776-02
|
$636,299
|
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
ALK causes TGF-beta insensitivity in lung cancer cells
|
1R21CA209007-01
|
$172,369
|
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-18
|
$320,963
|
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epigenomic reprogramming driven by mutant ER? in metastatic breast cancer
|
1F31CA210385-01
|
$43,525
|
|
GATES, LEAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel targets that are deregulated by loss of PTEN
|
5R01CA108614-10
|
$288,103
|
|
JOHNSON, DEBORAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
The cell of origin of breast cancer metastasis
|
1R21CA202227-01
|
$172,369
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-03
|
$322,828
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
In Vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models
|
5U01CA199288-02
|
$578,693
|
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
New mechanisms of breast cancer metastasis and loss of estrogen receptor driven by 14-3-3
|
1R21CA198041-01A1
|
$206,843
|
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression
|
1R21CA205257-01
|
$206,843
|
|
MCGUIRE, SEAN
|
BAYLOR COLLEGE OF MEDICINE
|
Total relevant funding to Kidney Cancer for this search: $55,783,916
|